Difference between revisions of "Rocuronium"

Rocuronium
Trade names	Zemuron
	Clinical data
Drug class	Neuromuscular blocker
Routes of administration	Intravenous
	Dosage
	Rocuronium Standard; 0.6 mg/kg IV (Ideal body weight); Rapid sequence; 1.2 mg/kg IV (Ideal body weight); Defasciculation; 0.04 mg/kg IV (Ideal body weight); Maintenance (bolus); 0.1-0.2 mg/kg IV (Ideal body weight); Maintenance (infusion); 0.01-0.012 mg/kg/min IV (Ideal body weight); More information about this dose Weight kglbg Height cmminft Age yrmowk SexFM Indication Indication: Neuromuscular blockade Route Route: Intravenous Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth. 2010 Dec;105 Suppl 1:i16-23. doi: 10.1093/bja/aeq312. PMID: 21148651.; Gaszynski TM, Szewczyk T. Rocuronium for rapid sequence induction in morbidly obese patients: a prospective study for evaluation of intubation conditions after administration 1.2 mg kg⁻¹ ideal body weight of rocuronium. Eur J Anaesthesiol. 2011 Aug;28(8):609-10. doi: 10.1097/EJA.0b013e32834753d0. PMID: 21562423.; Kim KN, Kim KS, Choi HI, Jeong JS, Lee HJ. Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration. Korean J Anesthesiol. 2014 Jun;66(6):451-6. doi: 10.4097/kjae.2014.66.6.451. Epub 2014 Jun 26. PMID: 25006369; PMCID: PMC4085266.;
	Pharmacodynamics
Mechanism of action	Nicotinic acetylcholine antagonism
	Pharmacokinetics
Onset of action	Standard Intubating Dose: 1.5 minutes Rapid Sequence Induction Dose: 90 seconds
Duration of action	35-75 minutes (Dose Dependent)
	Physical and chemical data
	Article quality
Editor rating	Unrated
User likes	0

Latest revision as of 13:27, 22 December 2022

Rocuronium is an intermediate duration non-depolarizing muscle relaxant.

Uses

Contraindications

Absolute contraindications

Precautions

Pharmacology

Pharmacodynamics

Mechanism of action

Rocuronium is a competitive nicotinic acetylcholine receptor antagonist. By blocking acetylcholine from binding it inhibits depolarization.^[1]

Adverse effects

Pharmacokinetics

Onset for 0.6 - 0.8 mg/kg Dose: 1.5 minutes

Onset for 0.9 - 1.2 mg/kg Dose: 60 - 90 seconds^[1]

Chemistry and formulation

Monoquaternary steroid non-depolarizing muscle relaxant.^[1]

History

References

↑ ^{Jump up to: 1.0} ^1.1 ^1.2 Butterworth IV, John F.; Mackey, David C.; Wasnick, John D. (2022), "Neuromuscular Blocking Agents", Morgan & Mikhail’s Clinical Anesthesiology (7 ed.), New York, NY: McGraw-Hill Education, retrieved 2022-12-22

Top contributors: Chris Rishel and Sydney Caley

[:0-1] {Jump up to: 1.0} ^1.1 ^1.2 Butterworth IV, John F.; Mackey, David C.; Wasnick, John D. (2022), "Neuromuscular Blocking Agents", Morgan & Mikhail’s Clinical Anesthesiology (7 ed.), New York, NY: McGraw-Hill Education, retrieved 2022-12-22

[1]

@@ Line 6: / Line 6: @@
 | contraindications =
 | routes = Intravenous
-| dosage = Intravenous
+| dosage =
-- Standard Intubation Dose: 0.6 mg/kg
-- Rapid Sequence Intubation Dose: 1.2 mg/kg
-- Defasciculating Dose: 0.1 mg/kg
 | halflife_redistribution =
 | protein_binding =